rezvilutamide rezvilutamide rezvilutamide (inn), sold under the brand name ariane, is a nonsteroidal antiandrogen which is approved for the treatment of prostate cancer in china and is or was under development for the treatment of breast cancer. it is a selective androgen receptor antagonist with reduced brain distribution compared to the structurally related nonsteroidal antiandrogen enzalutamide. the drug was developed by jiangsu hengrui medicine. other structural analogues of rezvilutamide that are also used as antiandrogens besides enzalutamide include apalutamide and proxalutamide. rezvilutamideclinical dataother namesshr3680drug classnonsteroidal antiandrogenidentifiers iupac name 4-phenyl]-4,4-dimethyl-5-oxo-2-sulfanylideneimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile cas number1572045-62-5pubchem cid89995232unii70fjn2aw22chemical and physical dataformulac22h20f3n3o4smolar mass479.47 g·mol−13d model (jsmol)interactive image smiles cc1(c(=o)n(c(=s)n1c2=cc=c(c=c2)oc(co)o)c3=cc(=c(c=c3)c#n)c(f)(f)f)c inchi inchi=1s/c22h20f3n3o4s/c1-21(2)19(31)27(15-4-3-13(10-26)18(9-15)22(23,24)25)20(33)28(21)14-5-7-17(8-6-14)32-12-16(30)11-29/h3-9,16,29-30h,11-12h2,1-2h3/t16-/m0/s1key:krbmoyiwqczvha-inizcteosa-n